The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.

Lung cancer treatment has witnessed a revolution in recent years, largely driven by the increasing understanding of genetics ...

and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs ...

Ferroptosis offers new strategies to combat treatment resistance in digestive tract cancers, enhancing the efficacy of ...

The global burden of digestive tract tumors is profound, with these cancers accounting for nearly half of all malignant tumors worldwide. Despite ...

Resistance to therapies targeting the epidermal growth factor receptor (EGFR) pathway also appears to be ... effectively sensitizes KRAS-mutant colorectal cancer cells to treatment, highlighting ...

Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...

Co-opted Pathways Required by Oncogenic KRAS to Sustain Lung Tumorigenesis Oncogenic KRAS relies on additional pathways that are engaged downstream of these effectors or are required indirectly as ...

every aspect of the KRAS pathway, adjacent downstream, and develop a biomarker that could impact account for all of that diversity.” What Genialis did was to train the biomarker on the 1-million ...